Company: LENZ
Filing Date: 2025-09-30
Form Type: 8-K
Source: 0001815776-25-000062
Chunk: 1

Company: LENZ Therapeutics, Inc.
Filing Date: 2025-09-30
Form: 8-K
Item: Item 8.01
Chunk 1
---
Item 8.01 Other Events.

As set forth above, on September 30, 2025, LENZ announced that VIZZ (aceclidine ophthalmic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults, is now available. Professional product sample distribution by LENZ's sales force to optometrists and ophthalmologists has been initiated nationwide. Commercial product shipments will be initiated to consumers in October through LENZ's ePharmacy partner and is anticipated to be broadly available, including via retail pharmacies, by mid-Q4 2025.

Item 9.01 Financial Statements and Exhibits.